Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- PMID: 26765102
- DOI: 10.1016/j.ejca.2015.11.016
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Abstract
Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting tumour responses. By unbalancing the immune system, these new immunotherapies also generate dysimmune toxicities, called immune-related adverse events (IRAEs) that mainly involve the gut, skin, endocrine glands, liver, and lung but can potentially affect any tissue. In view of their undisputed clinical efficacy, anti-CTLA-4 and anti-PD-1 antibodies are entering in the routine oncological practice, and the number of patients exposed to these drugs will increase dramatically in the near future. Although steroids can be used to treat these IRAEs, the associated immunosuppression may compromise the antitumour response. Oncologists must be ready to detect and manage these new types of adverse events. This review focuses on the mechanisms of IRAE generation, putative relationship between dysimmune toxicity and antitumour efficacy, as a basis for management guidelines.
Keywords: Anti-PD-1 antibody; Cytotoxic T-lymphocyte-associated antigen 4; Immune checkpoint blockade; Immune-related adverse events; Tumour neoantigen.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
New insight in endocrine-related adverse events associated to immune checkpoint blockade.Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 31983543 Review.
-
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3. Am J Clin Dermatol. 2018. PMID: 29256113 Review.
-
Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.Front Immunol. 2019 Sep 26;10:2254. doi: 10.3389/fimmu.2019.02254. eCollection 2019. Front Immunol. 2019. PMID: 31616428 Free PMC article. Review.
-
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.Am Soc Clin Oncol Educ Book. 2013. doi: 10.14694/EdBook_AM.2013.33.e280. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714523 Review.
-
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.Curr Cancer Drug Targets. 2015;15(6):452-62. doi: 10.2174/156800961506150805145120. Curr Cancer Drug Targets. 2015. PMID: 26282545 Review.
Cited by
-
Association Between the Immune Checkpoint Inhibitor Durvalumab and Myasthenia Gravis: A Comprehensive Review.Cureus. 2024 Sep 3;16(9):e68542. doi: 10.7759/cureus.68542. eCollection 2024 Sep. Cureus. 2024. PMID: 39364500 Free PMC article. Review.
-
Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis.Cureus. 2024 Aug 28;16(8):e68043. doi: 10.7759/cureus.68043. eCollection 2024 Aug. Cureus. 2024. PMID: 39347217 Free PMC article. Review.
-
Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects.Cells. 2024 Sep 11;13(18):1526. doi: 10.3390/cells13181526. Cells. 2024. PMID: 39329710 Free PMC article. Review.
-
Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.PLoS One. 2024 Sep 23;19(9):e0310808. doi: 10.1371/journal.pone.0310808. eCollection 2024. PLoS One. 2024. PMID: 39312569 Free PMC article.
-
Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes.Clin Transl Oncol. 2024 Sep 18. doi: 10.1007/s12094-024-03707-x. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39294513
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials